CD276 and neoplasm: The results showed that immune suppressive molecules, such as PDCD1, TNFSF9, TNFSF4, TNFSF14, TNFRSF8, TNFRSF4, TNFRSF18, TMIGD2, PDCD1LG2, CD86, CD70, CD274 (PD-L1), CD276 (B7-H3), CD244, BTNL2 and ADORA2A, were elevated in the high-risk group, suggesting that patients in the high-risk group have a worse anti-tumor immune response (Fig. 10e).